Forty years of the International Association for Study of Lung Cancer Pathology Committee

Journal of Thoracic Oncology

Volumn 9, Issue 12, 2014, Pages 1740-1749

  Tsao, Ming Sound ^a   Travis, William D ^b   Brambilla, Elisabeth ^c   Nicholson, Andrew G ^d   Noguchi, Masayuki ^e   Hirsch, Fred R ^f  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c HÔPITAL MICHALLON   (France)

^d ROYAL BROMPTON HOSPITAL   (United Kingdom)

^e UNIVERSITY OF TSUKUBA   (Japan)

^f UNIVERSITY OF COLORADO CANCER CENTER   (United States)

Author keywords

Anaplastic lymphoma kinase; Epidermal growth factor receptor; Histopathology; Molecular pathology; World Health Organization classification

Indexed keywords

ARTICLE; CANCER CLASSIFICATION; CANCER PATIENT; HUMAN; LUNG ADENOCARCINOMA; LUNG CANCER; MEDICAL SOCIETY; PATHOLOGIST; PATIENT CARE; PERSONALIZED MEDICINE; PRIORITY JOURNAL; SMALL CELL LUNG CANCER; WORLD HEALTH ORGANIZATION; LUNG TUMOR; NON SMALL CELL LUNG CANCER; PATHOLOGY; PHARMACY AND THERAPEUTICS COMMITTEE;

CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; PHARMACY AND THERAPEUTICS COMMITTEE; SMALL CELL LUNG CARCINOMA;

EID: 84927625575     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0000000000000356     Document Type: Review

References (50)

1. World Health Organization. Histological typing of lung tumors. Geneva: World Health Organization, 1981.
2. Radice PA, Matthews MJ, Ihde DC, et al. The clinical behavior of "mixed" small cell/large cell bronchogenic carcinoma compared to "pure" small cell subtypes. Cancer 1982;50:2894-2902.
3. Gazdar AF, Carney DN, Nau MM, Minna JD. Characterization of variant subclasses of cell lines derived from small cell lung cancer having distinctive biochemical, morphological, and growth properties. Cancer Res 1985;45:2924-2930.
4. Matthews MJ, Rozencweig M, Staquet MJ, Minna JD, Muggia FM. Long-term survivors with small cell carcinoma of the lung. Eur J Cancer 1980;16:527-531.
5. Bepler G, Neumann K, Holle R, Havemann K, Kalbfleisch H. Clinical relevance of histologic subtyping in small cell lung cancer. Cancer 1989;64:74-79.
6. Hirsch FR, Matthews MJ, Aisner S, et al. Histopathologic classification of small cell lung cancer. Changing concepts and terminology. Cancer 1988;62:973-977.
7. Roggli VL, Vollmer RT, Greenberg SD, McGavran MH, Spjut HJ, Yesner R. Lung cancer heterogeneity: a blinded and randomized study of 100 consecutive cases. Hum Pathol 1985;16:569-579.
8. Travis WD, Colby TV, Corrin B, Shimosato Y, Brambilla E; In Collaboration with L. H. Sobin and Pathologists from 14 Countries. Histological Typing of Lung and Pleural Tumors. Berlin: Springer, 1999.
9. Noguchi M, Morikawa A, Kawasaki M, et al. Small adenocarcinoma of the lung. Histologic characteristics and prognosis. Cancer 1995;75:2844-2852.
10. Beasley MB, Thunnissen FB, Brambilla E, et al. Pulmonary atypical carcinoid: predictors of survival in 106 cases. Hum Pathol 2000;31:1255-1265.
11. Burke L, Flieder DB, Guinee DG, et al. Prognostic implications of molecular and immunohistochemical profiles of the Rb and p53 cell cycle regulatory pathways in primary non-small cell lung carcinoma. Clin Cancer Res 2005;11:232-241.
12. Debelenko LV, Swalwell JI, Kelley MJ, et al. MEN1 gene mutation analysis of high-grade neuroendocrine lung carcinoma. Genes Chromosomes Cancer 2000;28:58-65.
13. Debelenko LV, Brambilla E, Agarwal SK, et al. Identification of MEN1 gene mutations in sporadic carcinoid tumors of the lung. Hum Mol Genet 1997;6:2285-2290.
14. He P, Varticovski L, Bowman ED, et al. Identification of carboxypeptidase E and gamma-glutamyl hydrolase as biomarkers for pulmonary neuroendocrine tumors by cDNA microarray. Hum Pathol 2004;35:1196-1209.
15. Nicholson SA, Beasley MB, Brambilla E, et al. Small cell lung carcinoma (SCLC): a clinicopathologic study of 100 cases with surgical specimens. Am J Surg Pathol 2002;26:1184-1197.
16. Beasley MB, Lantuejoul S, Abbondanzo S, et al. The P16/cyclin D1/Rb pathway in neuroendocrine tumors of the lung. Hum Pathol 2003;34:136-142.
17. Toyooka S, Toyooka KO, Maruyama R, et al. DNA methylation profiles of lung tumors. Mol Cancer Ther 2001;1:61-67.
18. Burke L, Khan MA, Freedman AN, et al. Allelic deletion analysis of the FHIT gene predicts poor survival in non-small cell lung cancer. Cancer Res 1998;58:2533-2536.
19. Guinee DG Jr, Travis WD, Trivers GE, et al. Gender comparisons in human lung cancer: analysis of p53 mutations, anti-p53 serum antibodies and C-erbB-2 expression. Carcinogenesis 1995;16:993-1002.
20. Travis WD, Gal AA, Colby TV, Klimstra DS, Falk R, Koss MN. Reproducibility of neuroendocrine lung tumor classification. Hum Pathol 1998;29:272-279.
21. Travis WD, Brambilla E, Müller-Hermelink HK, Harris CC. Pathology and Genetics: Tumours of the Lung, Pleura, Thymus and Heart. Lyon: IARC, 2004.
22. Miller VA, Hirsch FR, Johnson DH. Systemic therapy of advanced bronchioloalveolar cell carcinoma: challenges and opportunities. J Clin Oncol 2005;23:3288-3293.
23. Travis WD, Garg K, Franklin WA, et al. Evolving concepts in the pathology and computed tomography imaging of lung adenocarcinoma and bronchioloalveolar carcinoma. J Clin Oncol 2005;23:3279-3287.
24. Lim E, Goldstraw P, Nicholson AG, et al. Proceedings of the IASLC International Workshop on Advances in Pulmonary Neuroendocrine Tumors 2007. J Thorac Oncol 2008;3:1194-1201.
25. Travis WD, Brambilla E, Noguchi M, et al. International association for the study of lung cancer/American thoracic society/European respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 2011;6:244-285.
26. Thunnissen E, Beasley MB, Borczuk AC, et al. Reproducibility of histopathological subtypes and invasion in pulmonary adenocarcinoma. An international interobserver study. Mod Pathol 2012;25:1574-1583.
27. Lindeman NI, Cagle PT, Beasley MB, et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J Thorac Oncol 2013;8:823-859.
28. MS Tsao, FR Hirsch, Y Yatabe (Eds.). IASLC ATLAS of ALK Testing in Lung Cancer. Aurora, CO: IASLC Press, 2013.
29. Auerbach O, Hammond EC, Garfinkel L. Changes in bronchial epithelium in relation to cigarette smoking, 1955-1960 vs. 1970-1977. N Engl J Med 1979;300:381-386.
30. Oswald NC, Hinson KF, Canti G, Miller AB. The diagnosis of primary lung cancer with special reference to sputum cytology. Thorax 1971;26:623-627.
31. Kanhouwa SB, Matthews MJ. Reliability of cytologic typing of lung cancer. Acta Cytol 1976;20:229-232.
32. Yesner R. Classification of lung-cancer histology. N Engl J Med 1985;312:652-653.
33. Wu AH, Henderson BE, Thomas DC, Mack TM. Secular trends in histologic types of lung cancer. J Natl Cancer Inst 1986;77:53-56.
34. Dodds L, Davis S, Polissar L. A population-based study of lung cancer incidence trends by histologic type, 1974-81. J Natl Cancer Inst 1986;77:53-56.
35. Brambilla E, Moro D, Veale D, et al. Basal cell (basaloid) carcinoma of the lung: a new morphologic and phenotypic entity with separate prognostic significance. Hum Pathol 1992;23:993-1003.
36. Moro D, Brichon PY, Brambilla E, Veale D, Labat F, Brambilla C. Basaloid bronchial carcinoma. A histologic group with a poor prognosis. Cancer 1994;73:2734-2739.
37. Park IW, Wistuba II, Maitra A, et al. Multiple clonal abnormalities in the bronchial epithelium of patients with lung cancer. J Natl Cancer Inst 1999;91:1863-1868.
38. Miller VA, Kris MG, Shah N, et al. Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced nonsmallcell lung cancer. J Clin Oncol 2004;22:1103-1109.
39. Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007;448:561-566.
40. Shaw AT, Yeap BY, Mino-Kenudson M, et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol 2009;27:4247-4253.
41. Kwak EL1, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med. 2010;363:1693-1703.
42. Onuki N, Wistuba II, Travis WD, et al. Molecular changes in the spectrum of neuroendocrine lung tumors. Cancer 1999;85:600-607.
43. Travis WD, Garg K, Franklin WA, et al. Bronchioloalveolar carcinoma and lung adenocarcinoma: the clinical importance and research relevance of the 2004 World Health Organization pathologic criteria. J Thorac Oncol 2006;1(9 Suppl):S13-S19.
44. Austin JH, Garg K, Aberle D, et al. Radiologic implications of the 2011 classification of adenocarcinoma of the lung. Radiology 2013;266:62-71.
45. Van Schil PE, Asamura H, Rusch VW, et al. Surgical implications of the new IASLC/ATS/ERS adenocarcinoma classification. Eur Respir J 2012;39:478-486.
46. Travis WD, Brambilla E, Van Schil P, et al. Paradigm shifts in lung cancer as defined in the new IASLC/ATS/ERS lung adenocarcinoma classification. Eur Respir J 2011;38:239-243.
47. Travis WD, Brambilla E, Noguchi M, et al; American Thoracic Society. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society: international multidisciplinary classification of lung adenocarcinoma: executive summary. Proc Am Thorac Soc 2011;8:381-385.
48. Travis WD, Brambilla E, Noguchi M, et al. Diagnosis of lung adenocarcinoma in resected specimens: implications of the 2011 International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification. Arch Pathol Lab Med 2013;137:685-705.
49. Travis WD, Brambilla E, Noguchi M, et al. Diagnosis of lung cancer in small biopsies and cytology: implications of the 2011 International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification. Arch Pathol Lab Med 2013;137:668-684.
50. Pelosi G, Rindi G, Travis WD, Papotti M. Ki-67 antigen in lung neuroendocrine tumors: unraveling a role in clinical practice. J Thorac Oncol 2014;9:273-284.